PLIANT THERAPEUTICS, INC.
Income Statement
| Line Item | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $248.0K | $1.3M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $38.8M | $47.8M | $45.6M | $37.1M | $33.2M | $32.3M | $33.0M | $29.3M |
| SG&A Expense | $14.5M | $14.3M | $15.0M | $15.2M | $13.9M | $15.3M | $14.6M | $14.2M |
| Operating Income | $-53.3M | $-62.0M | $-60.6M | $-52.4M | $-47.0M | $-47.7M | $-47.3M | $-42.1M |
| Operating Margin | — | — | — | — | — | — | -19,083.9% | -3,160.3% |
| Interest Expense | — | — | — | $445.0K | $320.0K | $317.0K | $319.0K | $311.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-49.7M | $-57.8M | $-55.9M | $-47.0M | $-41.1M | $-41.5M | $-41.2M | $-37.5M |
| Net Margin | — | — | — | — | — | — | -16,609.7% | -2,818.9% |
| EPS (Basic) | $-0.82 | $-0.95 | $-0.92 | $-0.78 | $-0.68 | $-0.70 | $-0.70 | $-0.67 |
| EPS (Diluted) | $-0.82 | $-0.95 | $-0.92 | $-0.78 | $-0.68 | $-0.70 | $-0.70 | $-0.67 |
| Shares Outstanding (Basic) | 60.5M | 60.7M | 60.4M | 60.2M | 58.7M | 59.7M | 59.2M | 56.1M |
| Shares Outstanding (Diluted) | 60.5M | 60.7M | 60.4M | 60.2M | 58.7M | 59.7M | 59.2M | 56.1M |
| Dividends Per Share | — | — | — | $0.00 | — | — | — | $0.00 |